Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Development and Nested Cross-Validation of Explainable Machine-Learning Models for Predicting the Risk of Propofol-Associated Hypertriglyceridemia in Critically-Ill, Mechanically-Ventilated Patients
Deng, Jiawen , Heybati, Kiyan , Xie, Guohao , Hemang, Y., Deng, J , Xie, G., Poudel, K., Hemang, Y.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5690-A5690

10.1164/ajrccm.2025.211.abstracts.a5690 Get It

Abstract RATIONALE Propofol is the first-line sedative for critically-ill, mechanically-ventilated patients, but it can increase serum triglyceride levels. Machine-learning (ML) offers a promising approach for individualized risk stratification of propofol-associated hypertriglyceridemia, enabling proactive triglyceride monitoring and sedation optimization. This study aims to develop and validate ML models to predict hypertriglyceridemia risks in critically-ill patients receiving propofol. METHODS We analyzed retrospective data from adult ICU patients on mechanical ventilation receiving continuous propofol infusion for ≥24 hours across four Mayo Clinic sites from May 2018 to June 2023. The primary outcome was hypertriglyceridemia, defined as serum triglycerides >400 mg/dL within 10 days of starting propofol. Ten-fold cross-validation and leave-one-site-out nested cross-validation (LOSO-CV) were used for model tuning and external validation of our modeling process, respectively. Feature selection was conducted through a union of Boruta and least absolute shrinkage and selection operator (LASSO). While COVID status was a strong predictor of hypertriglyceridemia, we concurrently developed non-COVID models to ensure future relevance in non-pandemic settings. Six ML algorithms (logistic regression, support vector machines, random forests, LightGBM, XGBoost, and multilayer perceptrons) were tuned using Bayesian optimization to minimize cross-entropy loss. Classification thresholds were set to target sensitivity ≥80%. Model performance was evaluated using AUC-ROC, Brier score, sensitivity, and specificity. Models with the highest Youden's Index were designated the best-performing model. Model explainability was assessed using permutation importance and SHapley Additive exPlanations (SHAP). RESULTS We included 3922 eligible patients with triglyceride measurements. Of these, 3042 patients were COVID-negative and used for non-COVID modeling. The best-performing non-COVID models achieved an average AUC-ROC of 0.69 (95% confidence interval [CI] 0.68-0.70), Brier score of 0.12 (95% CI 0.09-0.14), sensitivity of 0.79 (95% CI 0.75-0.83), and specificity of 0.48 (95% CI 0.44-0.52) during LOSO-CV. The best-performing models that included COVID status achieved an average AUC-ROC of 0.71 (95% CI 0.70-0.72), Brier score of 0.13 (95% CI 0.10-0.16), sensitivity of 0.78 (95% CI 0.71-0.84), and specificity of 0.51 (95% CI 0.45 to 0.56) during LOSO-CV. The permutation importance results of the final non-COVID model are shown in the figure. CONCLUSION We have developed sensitive ML models for predicting hypertriglyceridemia risks in critically-ill patients receiving propofol. Although developed during the COVID-19 pandemic, the non-COVID models are more likely to have future relevance, and they have similar performance as models including COVID status. These models will be integrated into a web-based clinical calculator and undergo further validation in prospective studies.
Trainee Involvement and Outcomes in Patients With Rapid Response Activations
Friesen, Joelle N. , Wanberg, Erik J, Allman, Ava-Ann, Allman, A., Moraes, Alice Gallo de

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5623-A5623

10.1164/ajrccm.2025.211.abstracts.a5623 Get It

Abstract Rationale: Medical trainees are often involved in the care of hospitalized patients, yet there are minimal data about correlation of trainee involvement with outcomes for patients with rapid response team (RRT) activations. Methods: This was a retrospective single-center review of adult patients on a primary medicine service who had an RRT activation between January 1, 2023 and December 31, 2023. This study was approved by our hospital institutional review board. Patients were included if they were at least 18 years old and had a hospitalization with an RRT activation. Outcomes analyzed included transfer to the ICU, 90-day mortality, and goals of care discussions. A subset analysis was performed of patients who remained on the floor after RRT. Statistical analysis was performed with Pearson's chi-square and Kruskal-Wallis tests. Results: We analyzed 1686 adult patients who had an RRT activation within the study timeframe. Mean age was 67.3 years (SD 16.8), 792 (47.0%) were female, and 1489 (88.3%) identified as white. Trainees were involved with 1016 (60.3%) patients; 935 of these were on an internal medicine team and 81 were on a family medicine team. Patients were more likely to transfer to the ICU if they were on a primary floor team with trainee involvement (p = 0.006). There was no difference in goals of care discussion occurrence prior to RRT (p = 0.257) or 90-day mortality (p = 0.877). Subset analysis of patients who remained on the floor after RRT was performed. There was no difference in occurrence of goals of care discussions after RRT (p = 0.169), code status change (p = 0.237), or transition to comfort care (p = 0.381) for patients on teams with trainee involvement and those without. Of the 925 patients who remained on the floor after RRT, goals of care discussion occurred after RRT in 210 (22.7%). Conclusions: In this study, we demonstrate that trainee involvement does not correlate with occurrence of goals of care discussions either before or after RRT activations. Trainee involvement also does not correlate with 90-day mortality for patients with decompensation events. However, patients on teams with trainee involvement are more likely to transfer to the ICU as the result of an RRT activation. It is possible that this reflects the increased complexity of patients who are admitted to teaching services; however, further investigation is needed.
Seamless Shifts: Optimizing Patient Handoffs in a Mixed Medical-Surgical Intensive Care Unit at a Tertiary Care Hospital
Ahmed, N., Manjappachar, Nirmala, Zarrabian, Baharan, King, P M, Canepa, Sucell Pérez, Chalmers, Sarah , Ahmed, N., King, P., Heise, K.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5602-A5602

10.1164/ajrccm.2025.211.abstracts.a5602 Get It

Abstract Effective communication during handoffs and transitions of care is crucial, as over 50% of sentinel patient events are due to communication gaps, according to the Joint Commission. In our open multi-specialty Intensive Care Unit (ICU) at a tertiary care center, we noticed variability in handoff practices leading to provider dissatisfaction, delays in care and increased potential for errors. To address this, we developed and implemented a standardized handoff procedure. METHODS: A multi-disciplinary team comprised of fellow physicians, nursing and advanced practice provider (APP) leadership conducted an online anonymized baseline survey (B) in December 2023 in our open mixed ICU assessing multidisciplinary provider satisfaction in the process of transitioning patients out of the ICU. Based on this, we identified areas for improvement in the ICU transfer-out process, focusing on communication methods and handoff standardization. Between February and June 2024, we designed and posted signage near provider work areas to clearly designate the primary team based on the level of care and co-managing specialties. We also developed electronic record-based template dot phrases based on the I-PASS format to help standardize information provided during handoff, and ICU team members were educated on the use of the same. Post-implementation (PI) surveys were anonymously conducted in June 2024 to assess the impact of changes, with data analysis comparing pre- and post-implementation metrics, and regular feedback meetings facilitated iterative improvements. RESULTS: We received 40 survey responses (B =20 and PI=20). In the baseline survey, 65% identified room for improvement, particularly with the timing of provider handoffs, inconsistencies in transfer documentation, and clarity on the responsible medical team. Post-implementation survey results showed a 15% improvement with 80% reported no problems during the process, and 85% rated the clarity of the process as “very clear” and “clear,” with 15% neutral. Regarding staff communication, 90% rated it as “good” to “very good,” with 5% neutral. Dot phrase utilization was deemed “very helpful” to “helpful” by 54%, while 46% were neutral. The majority (95%) reported no challenges during the transfer-out process, and 80% were satisfied with the initiative's implementation. CONCLUSION: Our study highlights the impact of a multimodal approach in improving the process of ICU transitioning patients. We were able to improve the primary team identification with posted signage in the ICU.Using computer template-based dot phrases, we were also able to successfully improve satisfaction with the sign out process at time of transition out of the ICU level of care.
CEDAR General/Implementation
Strechen, Inna , Pickering, Brian W. , Smith-Stellflug, Jamie L, Hamann, Brianne R., Heise, Katherine J., Tiong, Ing , Argue, David P., Barwise, Amelia , Herasevich, Svetlana , Herasevich, Vitaly , Ridgeway, Jennifer L. , Chang, Yu‐Hui

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5597-A5597

10.1164/ajrccm.2025.211.abstracts.a5597 Get It

Abstract Rationale: Ongoing healthcare staffing shortages have prompted new care paradigms that incorporate remote care delivery to support timely detection of patient physiological deterioration through mechanisms other than clinician bedside evaluations. In partnership with institutional Information Technology, our team has developed a unique clinical informatics environment, known as the Advanced Medical Practice (AMP) platform, that incorporates data from multiple sources and platforms and supports remote observation of patients from the electronic intensive care unit(eICU). AMP takes advantage of technologies outside of vendor-supported EHRs, and its advanced user-interface design reduces information overload while incorporating real-time data from novel devices and sensors. We partnered with the hospital practice to co-develop a score within the AMP platform(Clinical Events Detection and Response[CEDAR]) that incorporates heart rate, blood pressure, respiratory rate, and SpO2 to stratify patient risk and generate deterioration alerts for the electronic ICU(eICU) team. This formative evaluation employed an implementation science approach to refine CEDAR and ensure it is acceptable to users and can be feasibly implemented in practice. Methods: The study team conducted this pilot work in the eICU at Mayo Clinic (Rochester, MN). We observed the eICU workflow and documented feedback from eICU staff in fieldnotes. eICU staff were asked to log issues in a tracking file during shifts. Issues were reviewed daily and discussed at multidisciplinary team meetings weekly. Observation and tracking data were coded to constructs in the Consolidated Framework for Implementation Research(CFIR 2.0) framework and mapped to Expert Recommendations for Implementation Change(ERIC) strategies that targeted key determinants. Results: Between 9/23/24 and 10/25/24 we completed 25 days of observations. Most identified issues related to technical/design issues like unclear vital trigger alerts (CFIR: Innovation trialability and design); staff knowledge of CEDAR functionality and attitudes about functionality, complexity, or relative advantage compared to current systems (CFIR: Inner setting access to knowledge and information and relative advantage); and difficulties incorporating CEDAR into workflow(CFIR: Inner setting/compatibility). Implementation strategies mapped to CFIR determinants included promoting adaptability of customized interface features; staging implementation scale-up with iterative improvements; providing local technical assistance; assessing for readiness and identifying facilitators and barriers; and conducting educational outreach visits. Conclusions: Formative evaluation during pilot studies are a critical step in the process of intervention development and testing. User engagement and frameworks from implementation science can identify issues of feasibility and inform strategies to ensure acceptability prior to intervention scale-up in clinical practice and readiness for conducting larger implementation studies.
A Cohort of Bronchiectasis and ANCA-associated Vasculitis (Suspected or Confirmed)
Alitelat, Alwatheq , Labban, M. El, Baqir, M., Doumat, George , Kanj, Amjad

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5563-A5563

10.1164/ajrccm.2025.211.abstracts.a5563 Get It

Abstract Background: Bronchiectasis is a recognized pulmonary manifestation of ANCA-associated vasculitides (AAV). Although positive AAV workup has been observed in patients with isolated airway diseases, without other systemic involvement, AAV workup is not routinely obtained in patients presenting with bronchiectasis. Patients with bronchiectasis and positive AAV workup may represent a distinct subgroup with unique characteristics and outcomes. Objectives: To establish a cohort of patients with bronchiectasis who also have a positive AAV workup (i.e., presence of ANCA by indirect immunofluorescence AND elevated antibodies to PR3 or MPO) and to describe their characteristics. METHODS: There were 944 patients across Mayo clinic sites with bronchiectasis (J47.9, J47.0 and J 47.1) who underwent AAV workup. Of these 315 (33.36%) had evidence of ANCA on immunofluorescence and an abnormal level of antibodies to PR3 or MPO. Chest CT scans were reviewed, and 118 patients were excluded because their pulmonary disease was mostly interstitial or had no clear bronchiectasis. Co-morbidities were evaluated using respective ICD-10 codes and respiratory cultures were collected. RESULTS: A total of 197 patients were identified with Bronchiectasis (76% female; mean age 66 years, BMI 25 kg/m2), 112 (56.8%) were diagnosed before antibody detection and 85 (43.1%) after. MPO (positive [>0.9] or equivocal [0.4-0.9]) was detected in 177 (89.8%) patients; PR3 (positive [>0.9] or equivocal [0.4-0.9]) in 34 (17.2%). P-ANCA and c-ANCA patterns occurred in 185 (94%) and 15 (4%) patients, respectively. The most common antigen-target/ANCA combinations were MPO/p-ANCA (177, 89.8%), PR3/p-ANCA (22, 11.2%), and PR3/c-ANCA (14, 7.1%). Comorbidities included asthma (66, 33.5%), COPD (58, 29.4%), GERD (64, 32.5%), hypothyroidism (56, 28.4%), and autoimmune/inflammatory conditions (e.g., rheumatoid arthritis [23, 11.7%], IBD [25, 12.7%]). Neurologic (42, 23.9%) and renal (25, 14.7%) manifestations occurred. Respiratory cultures (n=122) isolated yeast (57, 46.7%), Aspergillus (34, 27.9%), and Pseudomonas (30, 24.6%); Mycobacteria and other molds (e.g., Penicillium) each appeared in 23-24 patients (∼19%). Conclusion: This work identifies a cohort of patients with bronchiectasis who also have a positive AAV workup, mostly MPO/p-ANCA. While AAV workup is not routine for patients presenting for bronchiectasis evaluation, some patients in this cohort had primarily airway disease with an abnormal AAV workup, in the absence of other common manifestations of AAV. Further research on this cohort will be conducted to determine whether these patients represent a distinct group with unique characteristics, treatment patterns, and outcomes.
Gender Disparities in ICU Outcomes Among Patients With Interstitial Lung Disease
Viggiano, M., Li, Shifang , Skolnik, Avy A. , Sen, Ayan , Skolnik, A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5469-A5469

10.1164/ajrccm.2025.211.abstracts.a5469 Get It

Abstract IntroductionPatients with interstitial lung disease (ILD) who are admitted to the intensive care unit (ICU) face significant challenges, with high rates of morbidity and mortality. Despite the severity of outcomes in this population, the potential impact of gender disparities on ICU outcomes in ILD has not been well studied.MethodsWe analyzed data from the NIS spanning 2016 to 2018, focusing on adults (≥18 years) hospitalized with ILD (J84), and defined ICU stays using ICD codes for central line placement and mechanical ventilation. The NIS, part of the Healthcare Cost and Utilization Project, provides a weighted, nationally representative sample of U.S. hospitalizations. Demographic, clinical, and hospital characteristics were collected, with race/ethnicity categorized per NIS classifications. Multivariable logistic and linear regression models adjusted for potential confounders to evaluate gender differences in outcomes.ResultsOur study identified 810,295 adult hospitalizations with ILD, of which 42,080 required ICU-level care. Of these, 46.7% were female. Female ICU patients were younger (mean age 66.9 ± 13.8 vs. 69.1 ± 12.7, p<0.001), more likely to be African American (17.0% vs. 10.9%, p<0.001), and less likely to be Caucasian (63.7% vs. 69.2%, p<0.001). Females were more often from lower-income ZIP codes (33.2% vs. 38.3%, p<0.001) and had lower rates of tobacco use disorder (35.0% vs. 43.9%, p<0.001). Mortality was significantly lower in females (40.5% vs. 48.1%, p<0.001). After adjusting for confounders, female gender was independently associated with reduced mortality risk (adjusted odds ratio 0.77, 95% CI 0.70-0.84, p<0.001) and a shorter length of hospital stay (adjusted difference 1.15 days, 95% CI 0.54-1.77).ConclusionOur study highlights notable gender differences in outcomes for patients with ILD admitted to the ICU. Female patients had a significantly lower risk of mortality and shorter hospital stays than male patients, even after adjusting for key clinical and socioeconomic confounders. These findings are consistent with emerging evidence that biological sex and gender-related factors play a critical role in disease expression and outcomes in ILD.Several mechanisms may explain these gender disparities. Sex hormones, such as estrogen, have been shown to exert protective effects in pulmonary fibrosis models, potentially influencing the disease course in women. Incorporating these considerations into clinical practice and future research will be vital for advancing individualized, patient-centered medicine in ILD.
Which US States Support Unilateral Clinician Decisions to Decline Initiating or Maintaining Life-sustaining Treatment?
Huber, Michael , Parker, W.F., DeMartino, Erin S. , Piscitello, Gina M. , Huber, M., Lyons, Patrick G.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5391-A5391

10.1164/ajrccm.2025.211.abstracts.a5391 Get It

Abstract Rationale: Disparities in unilateral clinician decisions to decline initiating or maintaining life-sustaining treatment (LST) exist. We aimed to determine 1) which US state statutes support unilateral clinician decisions to decline initiating or maintaining LST; 2) what requirements, if any, must be met for these unilateral clinician decisions to occur; and 3) which state statutes address concerns for sociodemographic disparities associated with these decisions. Methods: Between September and October 2024, we used Fastcase, Casetext and official US state government websites to identify statutes for all US states and Washington, DC that addressed clinician decisions to decline to initiate or maintain LST. We defined reason of conscience as explicit mention of conscience, religion, ethics or moral reasons supporting unilateral clinician decision-making. Two reviewers independently analyzed each statute resolving disagreements with consensus adjudication. Results: Almost all (98%, n=50/51) statutes explicitly support unilateral clinician decisions to decline initiating or maintaining at least one form of LST. Reasons supporting these decisions varied across states including medical reasons only (16%), reasons of conscience only (22%), both medical reasons and reasons of conscience (35%), or no medical or conscience reason explicitly provided (25%). Medical reasons supporting unilateral clinician decisions included if LST was “medically ineffective” (24%), “contrary to medical standards” (14%), “medically inappropriate” (10%), or “nonbeneficial” (8%). For states supporting unilateral clinician decisions if LST was medically ineffective, 75% also supported LST to be declined for reason of conscience while 25% did not. When using medical reasons to support unilateral clinician decisions to decline LST, many statutes require that clinicians must first inform patient/surrogate of this decision (37%) and cooperate with transferring the patient to another clinician or institution (75%). Statutes rarely directly required clinicians to obtain a second medical opinion (8%), pursue a medical ethics committee review (6%), or address conflict (2%) in these situations. Although no state statutes explicitly acknowledged the existence of sociodemographic disparities associated with unilateral clinician decisions to initiate or maintain LST, 27% included guidance that addressed decisions to withhold or withdraw LST in specific marginalized groups. Conclusions: While almost all US state statutes allowed clinicians to decline to initiate or maintain LST, the reasons supporting and actions required to pursue these decisions varied. No statute explicitly addressed sociodemographic disparities associated with these decisions, which may perpetuate these disparities across the US.
Quantitative in Vivo Microscopic Assessment and Computer Aided Diagnosis of Early Interstitial Lung Disease Using Artificial Intelligence Based Endobronchial Optical Coherence Tomography
Nandy, Sreyankar , Berigei, S.R., Garcia-Moliner, Maria, Raphaely, Rebecca A., Calmo, N., Lee, J., Zhao, Sophia , Wright, C , Auchincloss, Hugh, Washko, G.R., Keyes, Colleen , Smith, Maxwell L. , VanderLaan, Paul A. , Calmo, Nery Matias , Yamamoto, Shuji , Shea, Barry S. , Lanuti, Michael D. , Sachdeva, Uma M , Washko, G.R., Herrmann, Markus D. , Hariri, Lida P.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5353-A5353

10.1164/ajrccm.2025.211.abstracts.a5353 Get It

Abstract Introduction: Endobronchial optical coherence tomography (EB-OCT) imaging has unique potential to diagnose and quantify early, microscopic disease changes and assess therapeutic responsivity in interstitial lung disease (ILD). However, training and time requirements for interpretation and quantitative evaluation of large volumetric EB-OCT datasets need to be optimized to facilitate clinical adoption. We develop and validate a computationally-efficient, rapid EB-OCT quantitative image analysis framework using artificial intelligence (AI) with deep learning architecture for 2D feature segmentation, 3D feature burden and spatial distribution mapping, and computer-aided diagnosis in early ILD subjects. Methods: Volumetric EB-OCT datasets, consisting of 2D cross-sectional images, were acquired from multiple locations in the bilateral lungs of ILD and healthy control subjects. EB-OCT features were manually segmented from cross-sectional images by an expert EB-OCT reader, including fibrosis, microscopic honeycombing, traction bronchiolectasis, normal parenchyma, and emphysema. EB-OCT images with corresponding feature segmentations were used to train and validate a multiclass convolutional neural network. The 2D AI-based segmentation model was subsequently evaluated against manual ‘ground truth’ segmentations for each feature in a de novo ‘test’ dataset of independent subjects using dice similarity score, precision, recall/sensitivity, specificity, and balanced accuracy. To generate 3D AI-based quantitative feature burden and spatial distribution maps, AI-based feature segmentation was performed on each EB-OCT 2D cross-sectional image within a volumetric imaging site. Three external pathologist readers independently interpreted 3D AI-based features maps for each EB-OCT imaging site acquired for a subject (without access to EB-OCT images) and provided a single diagnosis of usual interstitial pneumonia (UIP) or non-UIP ILD. Performance of computer-aided ILD diagnosis was compared against independently evaluated histopathology, clinical diagnosis, and prior EB-OCT image interpretation. Results: EB-OCT was acquired in 51 subjects: 30 in vivo early ILD, 5 in vivo non-ILD controls, and 16 ex vivo end-stage ILD. Overall pixel similarity between 2D manual and AI-based segmentation demonstrated high accuracy for each ILD feature (mean balanced accuracy 0.9). 3D quantitative AI-based feature maps demonstrated strong agreement (Spearman ρ0.87, p<0.001) between manual and AI-based segmentation. AI-based computer-aided diagnosis demonstrated 100% sensitivity/specificity for histologic UIP and clinical IPF for all pathologist readers, with improved diagnostic accuracy and significantly reduced training (45-minute training, 75% reduction) and interpretation time (<1 minute per subject for computer-aided diagnosis, 88% reduction) compared to EB-OCT image interpretation. Conclusion: The AI-based EB-OCT image analysis framework could expedite computer-aided diagnosis of early ILD and robust, quantitative assessment of microscopic disease burden, progression, and therapeutic responsivity.
Serum Inflammatory Markers as Predictors of Therapeutic Response to Anti-inflammatory Therapy in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
Kluanwan, Yanisa , Moua, Teng

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5347-A5347

10.1164/ajrccm.2025.211.abstracts.a5347 Get It

Abstract RATIONALE: Pulmonary fibrosis is recognized as the end result of multiple and recurrent pathways of lung injury. However, the role of chronic inflammation in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease (non-IPF f-ILD) remains inconclusive, as acute responses to anti-inflammatory treatment may vary. A reliable predictor for identifying patients who stand to benefit from treatment may be helpful for improving or sustaining lung function and avoiding adverse treatment effects. Our study aims to assess whether initial serum inflammatory markers, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), in the absence of clinically suspected infection or other causes of inflammation, are predictive of therapeutic response to anti-inflammatory medications in non-IPF f-ILD. METHODS: We performed a retrospective study comparing treatment response to anti-inflammatory therapy in non-IPF f-ILD stratified by initial CRP or ESR levels. Treatment was defined as corticosteroid or steroid-sparing agent for three months or more with lung function response defined as: 1) relative increase in percent predicted forced vital capacity (FVC%) > 5% in 6 months or > 10% or greater in 12 months; or 2) no change or any increase in FVC% if FVC% was declining prior to treatment initiation (relative decline in FVC% > 5% in the prior 6 months or > 10% in the prior 12 months). Logistic regression was used to predict treatment response as stratified by high vs low-to-normal inflammatory markers, with a mixed model for repeated measures for comparing FVC% change while treated. RESULTS: One hundred sixty-seven non-IPF f-ILD pts received anti-inflammatory therapy with baseline inflammatory markers stratified by high (N = 104) vs low-to-normal (N = 63) prior to treatment. Median age was 64 years with systemic rheumatic disease diagnosed in 58%. Treatment response was higher in patients with elevated inflammatory markers (55.77% vs. 34.92%, P = 0.011), even after adjustment for age, sex, baseline FVC%, and treatment duration (OR 2.45 [1.243-4.828], P = 0.010). FVC% slope from treatment initiation to discontinuation appeared to be increasing in patients with higher baseline inflammatory markers compared to those with low to normal marker levels (P = 0.003) (Figure1). CONCLUSION: Patients with non-IPF f-ILD and high initial inflammatory markers appear to be more acutely responsive to anti-inflammatory therapy with slower FVC decline or improvement over time while on treatment. These findings suggest baseline serum CRP and ESR may be reliable predictors of treatment response and direct treatment duration and intensity for efficacy or reducing adverse effects.
Implementation and Impact of a Results-driven Protocol in the Pulmonary Function Laboratory
Tran, Megan , Gust, K., Lee, A.S., Scrodin, M. Dulohery, Farah, Wigdan , Tran, M.M., Niven, Alexander S. , Gust, K.A., Lim, Kaiser G.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5328-A5328

10.1164/ajrccm.2025.211.abstracts.a5328 Get It

Abstract Introduction: The variety of pulmonary function tests (PFTs) offered in the pulmonary function lab (PFL) can confuse providers unfamiliar with the clinical role of the individual components of the PFT, potentially leading to repeat tests, diagnostic delays, patient burden, and reduced lab efficiency. We hypothesized that a symptom- and diagnosis-based ordering set will reduce the need for repeat testing visits. Methods: Baseline data (June 2022-June 2023) were first collected to establish PFL performance benchmarks and identify common reasons for incomplete or repeat PFL visits. We then implemented an electronic order set reflecting the clinical need of the PFT, based on symptoms, diagnoses, suspected diagnoses, or other common clinical indication in addition to a physician-supervised, results-driven protocol to allow de-escalation of testing when appropriate The pre-implementation data was compared to the post-implementation data (July 2023-June 2024), evaluating for its impact on PFL access, utilization of the specific PFT components (e.g. methacholine challenge test, MCT), and on diagnoses. Results: During the study period 52,292 PFTs were performed during the pre-implementation phase compared to 58,310 tests in the post-implementation phase. Following intervention, the need for a second PFL visit for the same clinical indication decreased from 26% to 13% (p<0.0001). The same day PFL capacity increased by 3-4 patients per day. 80% of primary care providers reported the new order design was more intuitive and easier to use. Among the specific components of the PFT, there was a significant increase in the number MCTs being performed, from 2.5% to 4%, (p<0.0001), with a change rate ranging between 26 – 81% / month. In a subset analysis of 57 consecutive patients having MCTs, the primary indications were evaluation for cough or wheezing (57.9%), initial asthma evaluation (22.8%), and specifically requested by the ordering provider (19.3%). MCT was not performed in 23% due to a low baseline lung function, difficulty with repeatable efforts, recent bronchodilator administration, or due to complicating comorbidities. Of the 39 tests completed, 89% were deemed appropriate, with 32% having positive results and 42% ultimately diagnosed with asthma. Conclusions: A symptom and/or diagnosis guided ordering set for pulmonary function testing appears to improve the efficiency of the PFL, while improving provider experience, PFL access, as well as on patient burden and diagnoses. Further research is needed to determine potential benefits for provider decision-making and patient outcomes.